生命科学资讯

Novartis licenses radiopharma asset from Chinese biotech for $50M upfront

Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s

Novartis to build fourth US radiotherapy factory in Florida

Alnylam, INCOG and Novartis expand in US; Ember gets $16.5M Series A

Roche and Novartis close to price agreement with Trump - medwatch.com

Voyager jettisons 30 employees, Novartis hands back rights to 2 programs

Novartis notches another win for drug acquired in MorphoSys deal

Novartis to partner with AI-focused Relation on atopic diseases

ASH: Novartis details ianalumab's phase 3 win in rare blood disease

FDA raises CAR-T approval standards; Novartis bets on an AI startup

Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech

#ASH25: Will a biotech’s pivot away from obesity let it compete with Novartis in leukemia?

Terns drug shows potential to challenge Novartis’ blockbuster leukemia treatment

Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3

Novartis wins approval to use SMA gene therapy in older patients

Novartis was the sole bidder in $12B deal to buy Avidity

#ASH25: Kelonia’s first in vivo CAR-T data; Lilly, J&J and Novartis spell out Phase 3 wins

Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syngenta, Biocon, Biogen, F. Hoffmann-La Roche, Novartis, Novo Nordisk A/S, Pfizer, and Seagen - ResearchAndMarkets.com - Business Wire

Roche, Novartis underline U.S. plans after Trump pharma tariff announcement - Reuters